Maviret is now fully funded for people living with hepatitis C.
Maviret is a prescription medicine containing a combination tablet of 100mg of glecaprevir and 40mg of pibrentasvir. It is used to treat chronic (long-lasting) hepatitis C virus (HCV) in adults. It belongs to a group of medicines called direct-acting antiviral agents. Ask your doctor if Maviret is right for you.
Before taking Maviret, ensure you tell your doctor if you:
Everyone should have a Fibroscan before having treatment for hepatitis C. It is important to know how much scar tissue or damage is present.
If there is mild or moderate scarring in the liver:
However, if severe scar tissue (cirrhosis) is present in the liver:
If the Fibroscan test was unsuccessful, you should be referred to a specialist to assess your liver prior to treatment.
Being ‘cured’ of the hepatitis C virus means having a sustained virological response (SVR), which is when the virus cannot be detected three months after treatment. This is a complete cure from hepatitis C, as being free of the virus six months after treatment means it is unlikely the virus will ever return and the liver damage from hepatitis C will have been stopped. However, you are not immune from hepatitis C and you can become reinfected if exposed to the virus again.
If your treatment was successful and your liver is healthy (no cirrhosis), you will not need further follow-up. It is important to maintain a good diet and a healthy lifestyle. Clearing the virus this allows your liver time to recover. Your community nurse and/or hospital staff will talk to you about how you can stay healthy.
For more information about finishing treatment, read the article ‘So you’ve finished treatment… now what?‘ from issue 6 of Talking Hep C.